論文

国際誌
2021年6月3日

Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.

BMC research notes
  • Shotaro Nakanishi
  • ,
  • Masato Goya
  • ,
  • Mitsuyoshi Tamaki
  • ,
  • Takuma Oshiro
  • ,
  • Seiichi Saito

14
1
開始ページ
227
終了ページ
227
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1186/s13104-021-05641-5

OBJECTIVE: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients. RESULTS: In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥ 8 (p = 0.004), an extent of disease value (EOD) of ≥ 2 (p = 0.004), and a 3-month PSA level > 1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. A 3-month PSA level > 1% of the pretreatment level was an independent predictor of OS (p = 0.004). Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level > 1% of the pretreatment level correlated with a poor prognosis.

リンク情報
DOI
https://doi.org/10.1186/s13104-021-05641-5
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34082809
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176613
ID情報
  • DOI : 10.1186/s13104-021-05641-5
  • PubMed ID : 34082809
  • PubMed Central 記事ID : PMC8176613

エクスポート
BibTeX RIS